StemCell Therapy

Big Market Research, one of the worlds prominent market research firms has released a new report on GlobalAnimal Stem Cell Therapy Market, The report expertise includes assessing new opportunities & sizing, identifying and evaluating complex global value chains (including key drivers, restraints and winning strategies). The report will help the vendor to strategize its positioning in the Animal Stem Cell Therapy Market projects around the globe. The detailed competitor profiling helped identify and understand the key strategies and growth drivers of its competitors. The report includes detailed profile of key competitors, pre/post launch surveys, go-to-market research, supplier selection surveys, industry demand/pain point surveys, pricing analysis, product testing, effectiveness studies, and product positioning studies.

The Animal Stem Cell Therapy Market research report includes:

The Animal Stem Cell Therapy Market report explore:

The Animal Stem Cell Therapy Market includes identification of important potential market demand, expected sale of these devices in the next 5 years, various price and demand sensitive scenarios were built to ascertain on the profitability of investing, customer analysis, and future price analysis.

Ask pdf sample copy of this premium research on Animal Stem Cell Therapy with Figures, Graphs and Tocs:https://www.bigmarketresearch.com/request-sample/4083483?utm_source=PRL&utm_medium=MWA

The Animal Stem Cell Therapy Market is also characterized by a highly complex value chain involving product manufacturers, material suppliers, technology developers, and manufacturing equipment developers. Partnerships between research organizations and the industry players help in streamlining the path from the lab to commercialization. In order to also leverage the first mover benefit, companies need to collaborate with each other so as to develop products and technologies that are unique, innovative and cost effective.

Several existing Animal Stem Cell Therapy Industry manufacturers, new start-ups as well as research organizations and universities are constantly coming up with innovative ideas. The Animal Stem Cell Therapy Market is expected to grow exponentially over the next five years with the emergence of new applications and cost competitive products.

Market players have been discussed and profiles of leading players including Top Key Companies:Medivet Biologics LLCVETSTEM BIOPHARMAJ-ARMU.S. Stem Cell, IncVetCell TherapeuticsCelavet Inc.Magellan Stem CellsKintaro Cells PowerAnimal Stem CareAnimal Cell TherapiesCell Therapy SciencesAnimacel

Animal Stem Cell Therapy Market By Product Type 2019-2025:DogsHorsesOthers

Based on type, the global market is segmented into the following sub-markets with annual revenue for 2015-2025 (historical and forecast) included in each section.

Animal Stem Cell Therapy Market By Application 2019-2025:Veterinary HospitalsResearch Organizations

Based on application, the global market is segmented into the following sub-markets with annual revenue for 2019-2025 (historical and forecast) included in each section.

Talk to our Analyst / Ask for a discount on Animal Stem Cell Therapy:https://www.bigmarketresearch.com/request-for-discount/4083483?utm_source=PRL&utm_medium=MWA

The comprehensive competitive landscape section of the report contains detailed analysis of the trends in mergers and acquisitions, agreements and partnerships, new product launches and so on in the Animal Stem Cell Therapy Market. This information will be very useful for existing players as well as new entrants in any market.

Geographically,Animal Stem Cell TherapyMarket is further analyzed into regions and country level analysis:North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Animal Stem Cell Therapy market forecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, and growth drivers of by analyzing the historical overall data of the considered market segments.

You May Also Like Our Other Top Trending Reports:

Read More:https://www.bigmarketresearch.com/report/3767216/global-x-ray-security-scanner-sale-insights-market?utm_source=PRL&utm_medium=MWA

About Us:

Big Market Researchhas a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us:Mr. Abhishek Paliwal5933 NE Win Sivers Drive, #205, Portland,OR 97220 United StatesDirect:+1-971-202-1575Toll Free:+1-800-910-6452E-mail:help@bigmarketresearch.com

The rest is here:
Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2027 - re:Jerusalem

Rheumatoid arthritis refers to an inflammatory disease of the supportive tissues of the body and the condition generally affects fingers and toes of human beings. This inflammation is caused by an abnormal response of the body to the normal functioning tissues. This leads to acute pain and malformed joints. Novel cells that are produced by regenerative centers of the body are called stem cells. These cells can be changed into any other type of cell in the body with just the right kind of stimulant. The growth of the global rheumatoid arthritis stem cell therapy market is likely to observe growth in its ability to demonstrate profound healing activity. It also helps in checking the arthritic condition. In addition to that, this therapy is capable of regenerating and reversing joint tissue in many cases, which is likely to pave way for rapid growth of the global rheumatoid arthritis stem cell therapy market in the years to come.

Get SampleCopy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6864

Ability to Diminish Pain and Inflammation to Bolster Demand in the Market

In present times, human umbilical cord tissue (allogeneic mesenchymal stem cells), fat-derived or adipose stem cells, and bone marrow transplant are utilized for the purpose of the rheumatoid arthritis stem cell therapy. As the condition becomes worse, the body starts autoimmune response and keeps on attacking the cells of the body. The global rheumatoid arthritis stem cell therapy market is estimated to gather momentum from its growing importance and popularity in specialty clinics, ambulatory surgical centers, and hospitals. This therapy comes with the excellent healing capabilities that can treat the entire system causing inflammation and joint pain.

Extensive growth opportunities of the global rheumatoid arthritis stem cell therapy market are likely to be influenced by the multiple benefits offered by this therapy. However, this therapy comes with its own share of disadvantages as well and is not an infallible method for healing arthritis. All though, this therapy is capable of assisting in the stabilization of the body immune system and diminish inflammation.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6864

Like Loading...

As Head of Marketing at TMR Research, Rohit brings to the table over a decade of experience in market research and Internet marketing. His dedication, perseverance, and passion for perfection have enabled him to achieve immense success in his field. Rohit is an expert at formulating new business plans and strategies to help boost web traffic. His interests lie in writing news articles on technology,healthcare and business.View all posts by Rohit Bhisey

Follow this link:
Rheumatoid Arthritis Stem Cell Therapy Market to Ride on Increased Prevalence of Rheumatoid Arthritis - TMR Research Blog

A team of UB researchers has published a paper in Nature Communications that is helping to define the best time to give a specific treatment to infants born with Krabbe disease (KD). This treatment has been found to prolong life for these infants for as long as a few years.

The paper was published online in Nature Communication Oct. 23.

Daesung Shin, assistant professor in the Department of Biotechnical and Clinical Laboratory Sciences and the Neuroscience Program, both in the Jacobs School of Medicine and Biomedical Sciences at UB, is the lead investigator. He also conducts research at UBs Hunter James Kelly Research Institute.

KD is an inherited disorder that destroys myelin, the protective coating of nerve cells in the brain and throughout the nervous system. In most cases, signs and symptoms of Krabbe disease develop in babies before 6 months of age, and the disease usually results in death by age 2. When it develops in older children and adults, the course of the disease can vary greatly.

The progressive neurologic disorder is caused by a deficiency of galactosylceramidase (GALC). GALC is an enzyme that breaks down galactosylceramide, an important component of myelin, which ensures the rapid transmission of nerve impulses.

Although there is no cure for KD, hematopoietic stem cell therapy (HSCT), a therapy that makes blood cells, reduces neurologic deterioration and improves developmental advances. These benefits are dependent on the severity of the disease at the time the stem cells are transplanted, and are only beneficial if delivered at a clinically defined pre-symptomatic time point before symptoms appear.

Even though it is widely accepted that early treatment is essential for the most positive outcome, the precise therapeutic window for treatment and what happens during this early time have never been elucidated, Shin says.

To address that issue, his team used mutations to create a novel mouse model of KD.

We engineered an inducible knockout mouse for the GALC gene deletion in specific cells at specific times, which provided us with the opportunity to directly ask when and where GALC enzyme is required for brain development, Shin explains.

We were particularly interested in the role of early developmental GALC function, he says. Our study not only revealed a key developmental process that requires GALC in the perinatal period, but also demonstrated that temporal GALC expression is likely a major contributor to brainstem development.

The researchers found that by increasing GALC levels at or before this newly defined perinatal period they could improve the effectiveness of therapeutic interventions for KD.

For the first time, our work showed the mechanistic evidence to explain why treatment must occur so early, with the defined critical postnatal period at days 4-6 in mice, and demonstrated that temporal GALC expression during this time is a major contributor to brainstem development, Shin says. Augmenting GALC levels at or prior to this newly defined period would likely improve the efficacy of therapeutic interventions for Krabbe patients.

While the time scale between mice and humans is considerably different, the sequence of key events in brain maturation between the two is consistent, he notes. It was estimated that the mouse nervous system at postnatal days 4-6 corresponds to a gestational age of 32 weeks in humans. Therefore, we anticipate that if our result is correct, then in utero treatments at, or prior to, 32 weeks should have better outcomes than conventional postnatal treatment for Krabbe babies.

Shin says his team will further identify which cell type needs to be targeted with therapy.

This work will directly impact the design of novel treatment options for KD patients, he says, noting that KD studies are at the basis of research on other, more common neurodegenerative diseases, such as multiple sclerosis and Parkinsons disease. Therefore, the teams work will have implications beyond KD.

Co-authors on the research were Nadav I. Weinstock, MD-PhD student, and Conlan Kreher, former masters student, both of the HJKRI and the Department of Biochemistry in the Jacobs School; Jacob Favret, research technician in the Department of Biotechnical and Clinical Laboratory Sciences; Lawrence Wrabetz and M. Laura Feltri, both co-directors of the HJKRI and members of the departments of Biochemistry and Neurology, as well as the Neuroscience Program.

Duc Nguyen and Ernesto R. Bongarzone of the Department of Anatomy and Cell Biology in the College of Medicine at the University of Illinois at Chicago also participated in the research.

The project was initiated with the support from Empire State development fund for HJKRI, and further developed and finalized by the R01, R56 and R03 grants from National Institutes for Health-National Institute for Neurological Disorders and Stroke awarded to Shin.

Go here to read the rest:
UB researcher narrows time window for administering specific treatment to infants with Krabbe disease - UB Now: News and views for UB faculty and...

BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced the expansion of its senior leadership team with the appointments of Michael Zdanowski as Chief Technology Officer, Farah Natoli as Head of Portfolio and Program Management and Mary West as Vice President, Clinical Operations.

The appointments of Michael, Farah and Mary build on our recently announced Series B financing to position Talaris for long-term success, as we advance our ongoing Phase 3 trial in living donor kidney transplant, prepare for additional Phase 2 trials next year and further realize the pipeline in a product potential of our unique cell therapy. Their accomplished and diverse backgrounds in manufacturing, portfolio strategy and clinical operations will be key assets guiding our future strategic direction, said Scott Requadt, Chief Executive Officer of Talaris. We are excited to welcome them to the Talaris team and look forward to their important contributions to Talaris continued success.

Mr. Zdanowski, Chief Technology Officer, is an accomplished leader in cell therapy manufacturing with over 25 years of experience. He has led manufacturing, logistics, quality and analytical development groups for stem cell organizations, and led design, construction and validation of facilities for commercial manufacturing for such firms as Pfizer Pharmaceuticals, Bayer Pharmaceuticals and Regeneron Pharmaceuticals. He was most recently Senior Vice President of BioPharmaceutical Operations for Medeor Therapeutics. Previously, Mr. Zdanowski was Vice President of GMP Operations for the New York Stem Cell Foundation and Vice President of Manufacturing for Mesoblast. Mr. Zdanowski has prepared FDA & EU CMC submissions for several late-stage stem cell products, including the BLA supporting FDA approval for the first allogeneic stem cell therapy product, HemaCord. He received his MBA from Columbia University and degrees in mechanical engineering and philosophy from the University of Pennsylvania.

Ms. Natoli, Head of Portfolio and Program Management, brings deep expertise in strategic direction and operational oversight of program advancement. She served most recently as Vice President, Program Management at Imara, in which capacity she provided strategic and operational leadership for Imaras global programs in sickle cell anemia and beta-thalassemia. Previously, Ms. Natoli served as the Executive Director, Program and Alliance Leadership at Bioverativ, a Sanofi Company; prior to that she held roles at AMAG Pharmaceuticals and FORUM Pharmaceuticals. Ms. Natoli holds an M.S. in natural sciences from the Roswell Park Cancer Institute, a division of State University of New York at Buffalo, and graduated with a B.S. in biology-chemistry and medical technology from Elmira College.

Ms. West, Vice President, Clinical Operations, brings an extensive background in complex clinical trial execution and team leadership. Most notably, she led all clinical operations at Boston-based Alnylam Pharmaceuticals for their lead product, Onpattro, in a successful registration trial that recruited over 220 patients globally and led to the historic approval of the product in late 2018. Ms. West previously served in clinical operations leadership roles at Paratek Pharmaceuticals, Momenta Pharmaceuticals, Acambis Pharmaceuticals, Millennium Pharmaceuticals and Pfizer Pharmaceuticals. Until recently, she was Head of Clinical Operations at BlueRock Therapeutics, where she implemented all of their GCP quality systems and laid the operational groundwork for their first IND. Ms. West received her M.S. in project management from Boston University and her B.S. in dietetics from Michigan State University.

About Talaris Therapeutics

Talaris Therapeutics, Inc. is a late-clinical stage biotechnology company that is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. Talaris is backed by a number of leading life sciences investors and maintains corporate offices in Boston, Mass., and its cell processing facility in Louisville, Ky. http://www.TalarisTx.com.

View original post here:
Talaris Therapeutics Expands Leadership Team With Appointments of Accomplished Executives in Manufacturing, Portfolio Strategy and Clinical Operations...

Global Nanoparticles in Biotechnology and Pharmaceuticals Market Professional Survey Research Report 2020-2028

The Lexis Business Insights added a new report Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 2024 in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers and restraints, profiles of major market players, segmentation and forecasting.

In 2020, the global Nanoparticles in Biotechnology and Pharmaceuticals Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2020-2025.

The global Nanoparticles in Biotechnology and Pharmaceuticals Market report offers a complete overview of the Nanoparticles in Biotechnology and Pharmaceuticals Market globally. It presents real data and statistics on the inclinations and improvements in global Nanoparticles in Biotechnology and Pharmaceuticals Markets. It also highlights manufacturing, abilities & technologies, and unstable structure of the market. The global Nanoparticles in Biotechnology and Pharmaceuticals Market report elaborates the crucial data along with all important insights related to the current market status.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Nanoparticles in Biotechnology and Pharmaceuticals market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-178849

Top key players @ Vertafore, Xdimensional Tech, Applied Systems, ACS, ITC, EZLynx, Sapiens/Maximum Processing, HawkSoft, Zywave, QQ Solutions, Insurance Systems, InsuredHQ, Buckhill, Agency Matrix, AllClients, AgencyBloc, Impowersoft, Jenesis Software, and Zhilian Software

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Nanoparticles in Biotechnology and Pharmaceuticals market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Nanoparticles in Biotechnology and Pharmaceuticals Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Nanoparticles in Biotechnology and Pharmaceuticals Market?

What are the key market trends impacting the growth of the Global Nanoparticles in Biotechnology and Pharmaceuticals Market?

What are the challenges to market growth?

Who are the key vendors in the Global Nanoparticles in Biotechnology and Pharmaceuticals Market?

What are the market opportunities and threats faced by the vendors in the Global Nanoparticles in Biotechnology and Pharmaceuticals Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Nanoparticles in Biotechnology and Pharmaceuticals Market;

3.) The North American Nanoparticles in Biotechnology and Pharmaceuticals Market;

4.) The European Nanoparticles in Biotechnology and Pharmaceuticals Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

Market Dynamics

The report analyzes the factors impacting the growth and the current market trends influencing the global Nanoparticles in Biotechnology and Pharmaceuticals market. Detailed pricing information with ex-factory prices of various products by key manufacturers form a crucial part of the report. Competition analysis, along with regional government policies affecting the Nanoparticles in Biotechnology and Pharmaceuticals market provides a detailed overview of the current status and prospects of the market. The impact of the ever-growing global population, coupled with technological advancements affecting the global Nanoparticles in Biotechnology and Pharmaceuticals market is also covered in the report.

Drivers & Constraints

The report provides extensive information about the factors driving the global Nanoparticles in Biotechnology and Pharmaceuticals market. Factors influencing the growth of the Nanoparticles in Biotechnology and Pharmaceuticals market, along with technological advancements, are discussed extensively in the report. The current restraints of the market, limiting the growth and their future impact are also analyzed in the report. The report also discusses the impact of rising consumer demand, along with global economic growth on the Nanoparticles in Biotechnology and Pharmaceuticals market.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.lexisbusinessinsights.com/request-sample-178849

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Statistical surveying reports are a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Read more from the original source:
Global Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis by Emerging Growth Factors and Revenue Forecast to 2026 - Zenit News

Two years ago, Dr. Ugur Sahin took the stage at a conference in Berlin and made a bold prediction. Speaking to a roomful of infectious disease experts, he said his company might be able to use its so-called messenger RNA technology to rapidly develop a vaccine in the event of a global pandemic.

At the time, Dr. Sahin and his company, BioNTech, were little known outside the small world of European biotechnology start-ups. BioNTech, which Dr. Sahin founded with his wife, Dr. zlem Treci, was mostly focused on cancer treatments. It had never brought a product to market. Covid-19 did not yet exist.

But his words proved prophetic.

On Monday, BioNTech and Pfizer announced that a vaccine for the coronavirus developed by Dr. Sahin and his team was more than 90 percent effective in preventing the disease among trial volunteers who had no evidence of having previously been infected. The stunning results vaulted BioNTech and Pfizer to the front of the race to find a cure for a disease that has killed more than 1.2 million people worldwide.

It could be the beginning of the end of the Covid era, Dr. Sahin said in an interview on Tuesday.

BioNTech began work on the vaccine in January, after Dr. Sahin read an article in the medical journal The Lancet that left him convinced that the coronavirus, at the time spreading quickly in parts of China, would explode into a full-blown pandemic. Scientists at the company, based in Mainz, Germany, canceled vacations and set to work on what they called Project Lightspeed.

There are not too many companies on the planet which have the capacity and the competence to do it so fast as we can do it, Dr. Sahin said in an interview last month. So it felt not like an opportunity, but a duty to do it, because I realized we could be among the first coming up with a vaccine.

After BioNTech had identified several promising vaccine candidates, Dr. Sahin concluded that the company would need help to rapidly test them, win approval from regulators and bring the best candidate to market. BioNTech and Pfizer had been working together on a flu vaccine since 2018, and in March, they agreed to collaborate on a coronavirus vaccine.

Since then, Dr. Sahin, who is Turkish, has developed a friendship with Albert Bourla, the Greek chief executive of Pfizer. The pair said in recent interviews that they had bonded over their shared backgrounds as scientists and immigrants.

We realized that he is from Greece, and that Im from Turkey, Dr. Sahin said, without mentioning their native countries long-running antagonism. It was very personal from the very beginning.

Dr. Sahin, 55, was born in Iskenderun, Turkey. When he was 4, his family moved to Cologne, Germany, where his parents worked at a Ford factory. He grew up wanting to be a doctor, and became a physician at the University of Cologne. In 1993, he earned a doctorate from the university for his work on immunotherapy in tumor cells.

Early in his career, he met Dr. Treci. She had early hopes to become a nun and ultimately wound up studying medicine. Dr. Treci, now 53 and the chief medical officer of BioNTech, was born in Germany, the daughter of a Turkish physician who immigrated from Istanbul. On the day they were married, Dr. Sahin and Dr. Treci returned to the lab after the ceremony.

The pair were initially focused on research and teaching, including at the University of Zurich, where Dr. Sahin worked in the lab of Rolf Zinkernagel, who won the 1996 Nobel Prize in medicine.

In 2001, Dr. Sahin and Dr. Treci founded Ganymed Pharmaceuticals, which developed drugs to treat cancer using monoclonal antibodies.

After several years they founded BioNTech as well, looking to use a wider range of technologies, including messenger RNA, to treat cancer. We want to build a large European pharmaceutical company, Dr. Sahin said in an interview with the Wiesbaden Courier, a local paper.

Even before the pandemic, BioNTech was gaining momentum. The company raised hundreds of millions of dollars and now has more than 1,800 people on staff, with offices in Berlin, other German cities and Cambridge, Mass. In 2018, it began its partnership with Pfizer. Last year, the Bill & Melinda Gates Foundation invested $55 million to fund its work treating H.I.V. and tuberculosis. Also in 2019, Dr. Sahin was awarded the Mustafa Prize, a biennial Iranian prize for Muslims in science and technology.

Dr. Sahin and Dr. Treci sold Ganymed for $1.4 billion in 2016. Last year, BioNTech sold shares to the public; in recent months, its market value has soared past $21 billion, making the couple among the richest in Germany.

The two billionaires live with their teenage daughter in a modest apartment near their office. They ride bicycles to work. They do not own a car.

Ugur is a very, very unique individual, Mr. Bourla, Pfizers chief executive, said in the interview last month. He cares only about science. Discussing business is not his cup of tea. He doesnt like it at all. Hes a scientist and a man of principles. I trust him 100 percent.

In Germany, where immigration continues to be a fractious issue, the success of two scientists of Turkish descent was cause for celebration.

With this couple, Germany has a shining example of successful integration, wrote the conservative-business site Focus.

A member of Parliament, Johannes Vogel, wrote on Twitter that if it was up to the far-right Alternative for Germany party, there would be no #BioNTech of Germany with zlem Treci & Ugur Sahin at the top.

If it were up to critics of capitalism and globalization, he added, there would be no cooperation with Pfizer. But that makes us strong: immigration country, market economy & open society!

Dr. Sahin has had little time for politics this year. BioNTech has been so busy developing a vaccine that the company has not finalized the financial details of its partnership agreement with Pfizer.

Trust and personal relationship is so important in such business, because everything is going so fast, Dr. Sahin said. We still have a term sheet and not yet a final contract on many things.

Dr. Sahin said he and Dr. Treci learned about efficacy data on Sunday night and marked the moment by brewing Turkish tea at home. We celebrated, of course, he said. It was a relief.

Christopher F. Schuetze contributed reporting from Berlin.

View original post here:
The Husband-and-Wife Team Behind the Leading Vaccine to Solve Covid-19 - The New York Times

More than 1,800 attendees already registered for the Global Bioeconomy Summit 2020. The conference takes place virtually from November 16 to 20.

First editions of the summit took place in Berlin in 2015 and 2018, this year it will be delivery fully virtually. The digital conference event with more than 1,800 participants is financed by the Federal Ministry of Education and Research (BMBF). The programme is brought together by the International Advisory Council on Global Bioeconomy (IAC), a body that was formed as part of the first GBS in 2015 and has been organizing the summits ever since.

5 plenary sessions, 12 interactive workshops, 100+ high-level speakers

With five plenary sessions and 12 interactive workshops, the conference covers a broad spectrum of discussions within the bioeconomy. For the first time, the IAC on Global Bioeconomy welcomes official partners from each continental region to strengthen the international character of the GBS. They are representing Japan, the ASEAN region, Eastern Africa, the European Union, and Latin America & the Caribbean.

The bioeconomy's role of solving global crises

More than 100 top-class speakers are taking part to discuss, among others, the bioeconomys role of solving global crises and effects of the corona crisis towards a sustainable bioeconomy as new economic strategy that stabilizes global economies. In the wake of pandemic, the global bioeconomy community will virtually come together for GBS2020 to explore uncharted territory and advance our sustainable development, Morakot Tanticharoen, Senior Advisor to the President of the National Science and Technology Development Agency Thailand (NSTDA). That Europe is willing to play its part in further establishing a biobased economy, is underlined by Peter Wehrheim, Head of Unit for the Bioeconomy and Food System at the European Commission:By scaling up its bioeconomy, the EU can become the first climate-neutral continent: I look forward to see many concrete best practice solutions for climate mitigation at this years Global Bioeconomy Summit.

However, speakers will not only refer to economy-driven potentials, but also will include social perspectives. The transition towards bio-based economies is not only about production but also about sustainable consumption. GBS2020 covers both sides of the equation and brings together experts from around the world to discuss regional differences in lifestyle and culture, says Torfi Jhannesson, Senior Adviser at the Nordic Council of Ministers. Top-class researchers such as Mary Maxon, Associate Laboratory Director for Biosciences, Lawrence Berkeley National Laboratory, will also contribute to the GBS. A vibrant bioeconomy is economic activity that is reinforced by the safe, secure, ethical and reciprocal use of biological data, as well as by international standards and norms in research and business operations, she says.

Communiqu and policy recommendations on how to further establish a sustainable bioeconomy

At the end of the virtual GBS conference week, a communiqu with policy recommendations developed and agreed by the International Advisory Council on Global Bioeconomy (IACGB) will be published and a shared vision on sustainable bioeconomy will be presented. For the first time the "Bioeconomy Youth Champions" will be chosen at the GBS. More than one hundred young bioeconomy players from all over the world have applied to take part in this competition, eight of which will be awarded and prepare their own Bioeconomy Roadmap.

Global expert survey and policy report results

The GBS will again provide the platform to present several international report results. The Global Expert Survey will shed light on sustainability governance for the bioeconomy and the Global Bioeconomy Policy Report summarizes again how countries across the globe have integrated bioeconomy into governmental action. According to this latest research, the trend of developing dedicated bioeconomy policy strategies has prevailed in recent years with 19 countries and macro-regions (Austria, Costa Rica, EU, Finland, France, Germany, Ireland, Italy, Japan, Latvia, Malaysia, Nordic Countries, Norway, South Africa, Spain, Thailand, UK, US, East Africa)[1] having adopted strategies since 2010. In parallel, according to the authors, bioeconomy development is increasingly driven by the engagement of macro-regional and international actors as well as stakeholders from science, civil society and industry.

Industry, policy and science expertise represented

In addition, the GBS program will include different perspectives on bioeconomy innovations for the market and investment developments, for instance in the alternative protein area. Several high-level representatives from policy, science, business and industry will take part, among them the following:

Virtual exhibition on bioeconomy

A virtual world exhibition on bioeconomy will show how specific products can contribute to global sustainability goals. There is also a media corner again with books, games, teaching material and graphic novels on the subject of bioeconomy. In addition, GBS participants from all over the world present video clips about projects or ventures - from start-ups to large corporations.

Evening reception with food start-ups and guided tours in natural history museums

And the GBS participants don't have to do without an evening reception either: On 19th November, among other things, they can look forward to a guided virtual tour in natural history museums in Berlin, Germany, and Paris, France. In addition, an innovative bio-based food menu is virtually presented by the food start-ups CellFarm, Knaerzje, Solar Foods and Yoll.

Excerpt from:
1800+ experts will join the Global Bioeconomy Summit - European Biotechnology News

TipRanks

Were a little over one week past the Presidential election, and the market reaction shows that that investors are pleased. While the election margins were razor thin, the will of the voters came through: they rejected Donald Trump, and his brash, in-your-face style, but they also rejected the Democratic Party on policy; the Dems lost seats in the House, will likely not take control of the Senate, and also lost ground at the State level. Americas voters seem to be tired of drama, whether it comes from Donald Trump or the Democrats push to the political left. They want a government that will simply plod straight along.And it looks like they will get just that. With power split in the White House and the Chambers of Congress, were about to be reminded of a feature of the checks and balance system: that gridlock is a result of a closely divided electorate. Change wont happen unless one side or the other gets a large majority, or a small majority over several terms. Neither of those is in the cards for now.The immediate result is a multi-day market rally. The implication is clear the markets sentiment has calmed since the election, and investors look forward to government settling into a more normal mode in the coming months.To this end, investors are sure to find solid options in the near term. Writing from Raymond James, analyst Ric Prentiss has recently published three reviews on mid-cap stocks, pointing out why, in his view, they offer high return potential with more settled markets in the coming year. The stocks all fit a profile: they are at the lower end of the mid-cap range, with market valuations between $2 billion and $3 billion; they inhabit the telecom ecosystem, and they all have, according to Raymond James, over 80% upside potential. We ran the the three through TipRanks database to see what other Wall Street's analysts have to say about them.Telephone & Data Systems (TDS)First on our list, Telephone & Data Systems, is a Chicago-based company providing a range of telecom services to over 6 million customers. The company offers broadband over cable and wireline, wireless products and services, and TV and voice services. TDS operates the countrys fifth-largest cellular carrier.TDS has dramatically outperformed expectations in 2020, despite the ongoing coronavirus. Revenues, at $1.32 billion, are about level with the pre-corona report ($1.34 billion in Q4 2019), while earnings jumped in 1Q20 and have remained high ever since. The Q3 earnings, at 66 cents, beat the forecast by 153%. It was an impressive performance, made more so by the 266% year-over-year growth.On another bright note for investors, TDS has maintained its dividend payment through the year. The 17-cent per common share payout annualizes to 68 cents, and offers a yield of 3.6%, nearly double the average yield found among S&P-listed companies.TDS has shown strong business through the year, but its weak point has been in the fiber and wireline niche. However, Raymond James Ric Prentiss looks at the half-full glass, noting: "WFH policies have continued to result in some slower approvals from municipalities and electrical utilities associated with building aerial fiber. And in some cases, TDS is pivoting to alternatives with better economics. Still, TDS Telecom grew fiber service addresses 5% y/y and is seeing better-than-expected take rates around 30-40%, depending on the market. Moreover, 34% of Wireline customers are now served by fiber, compared to 29% a year ago, and TDS expects acceleration throughout the rest of 2020."Prentiss rates TDS as a Strong Buy, and increased his price target by 6% to $34. At that level, he sees an 81% upside for the stock over the next months. (To watch Prentisss track record, click here)This stock also holds a Strong Buy rating from the analyst consensus, based on 3 unanimous Buy reviews set in recent weeks. Shares are priced at $18.73 and the average target of $34.83 suggests a one-year upside of 85.5%. (See TDS stock analysis on TipRanks)ViaSat, Inc. (VSAT)Next up, ViaSat, is a high-speed satellite broadband provider. The California company serves commercial and defense markets, building on the broad need, across industries, for secure communications.Social lockdown measures took a toll on the companys business, especially the shutdowns of airlines. Commercial air traffic relies heavily on satellite communications, and that slowdown is still weighing on ViaSat.The headwinds are partially offset by a backlog in services ordered. Revenues have remained stable over the past four quarters, between $530 million and $588 million, with the $554 million recorded in Q3 being solidly in the middle of that range. Earnings have bounced back into positive territory after turning negative in Q2. The third quarter EPS was only 3 cents, but that was a dramatic sequential improvement from the previous 20-cent net loss.In his look at VSAT, Prentiss notes, Government Systems and Commercial Networks remain strong, while the IFC business continues to navigate significant headwinds related to COVID-19 On the positive side, social distancing and Safer-At-Home policies are driving more residential broadband data usage and pushing ARPUs higherPrentiss rates VSAT an Outperform (i.e. Buy) while his $63 price target suggests an 87% upside potential.Overall, ViaSat gets a Moderate Buy rating from the analyst consensus, based on 3 reviews that include 2 Buys and 1 Hold. The shares have an average price target of $53.33, which implies a 12-month upside of 59% from the trading price of $33.39. (See VSAT stock analysis on TipRanks)EchoStar Corporation (SATS)Last but not least is EchoStar, another satellite operator. This company controls a constellation of communications satellites, offering satcom capabilities to the media and private enterprises, as well as both civilian and military US government agencies. In addition, EchoStar provides satellite broadband in 100 countries around the world.At the top line, EchoStar's revenues have held steady for the past three quarters, coming in at $465 million, $459 million, and $473 million. And while earnings were negative in Q1 and Q2, the Q3 results showed a net profit of 26 cents per share.The sequential Q3 improvements at the top and bottom lines come along with increases in the EchoStars subscriber base, to more than 1.54 million in total. The company also boasts a strong balance sheet, having more than $2.5 billion in cash on hand and no net debt.Covering SATS, Ric Prentiss is upbeat about near- and mid-term prospects. He writes, SATS [has] strategic optionality in a time when others, especially higher levered satellite companies, are cash starved facing significant maturities or capex programs we think a number of organic and inorganic growth options are being considered, including the future deployment of SBand spectrum after lining up anchor tenant(s). Lastly, we believe EchoStar's recently announced collaboration with Inmarsat to provide capacity for In-Flight Connectivity should provide over time high margin cash flows, and we note the deal is not exclusive.These comments back another Strong Buy rating, and Prentisss $57 target price indicates room for 123% growth in the next year. In terms of other analyst activity, it has been relatively quiet. 1 Buy and 1 Hold ratings assigned in the last three months add up to a Moderate Buy analyst consensus. In addition, the $43.50 average price target puts the upside potential at ~74%. (See SATS stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more:
Generex Biotechnology Announces Interview with Richard Purcell EVP of R&D on the Yo! Dr.Yo Show with an Update on the Ii-Key COVID Vaccine Program -...

FLORHAM PARK, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced its financial results for the third quarter ended September 30, 2020 and provided a business update.

Third Quarter 2020 and Recent Business Highlights

Successfully raised approximately $19 million via a public offering of common stock.

Initiated VERSATILE-002, a Phase 2 trial of PDS0101, our investigational drug candidate, in combination with standard of care KEYTRUDA for first-line treatment of patients with metastatic or recurrent HPV-positive head and neck cancer.

Initiated a Phase 2 study of PDS0101 in combination with standard of care chemoradiotherapy at the MD Anderson Cancer Center for treatment of locally advanced cervical cancer.

Continued development of PDS0103 in partnership with the National Cancer Institute.

Advanced co-development program with Farmacore with plans to move the PDS0203 COVID-19 vaccine into clinical development with the support of the Brazilian government.

Expanded Board of Directors with appointment of preeminent oncologist, Otis Brawley, M.D.

As a result of our teams dedicated efforts during the third quarter and our clinical partnerships with leading institutions in immuno-oncology, today PDS0101 is being evaluated in three phase 2 clinical trials for multiple HPV-associated cancers, commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotechnology. Furthermore, the successful equity raise we completed in August strengthened our balance sheet, ensuring we can continue to progress the clinical development of our oncology programs as well as expand both our oncology and infectious disease programs despite the challenges posed by the COVID-19 pandemic.

Third Quarter 2020 Financial Review

Story continues

For the third quarter of 2020, net loss was approximately $3.9 million, or $0.23 per basic share and diluted share, compared to a net loss of approximately $5.8 million, or $1.10 per basic share and diluted share for the third quarter of 2019.

Research and development expenses totaled approximately $2.1 million for the third quarter of 2020, compared to approximately $1.8 million for the same period in 2019, an increase of 12%. The increase was primarily attributable to an increase of $0.1 million in technical operations (manufacturing) and $0.3 million in clinical studies, offset by a decrease of $0.1 million in professional fees and $0.1 million in regulatory expenses.

For the third quarter of 2020, general and administrative expenses were approximately $1.8 million compared with approximately $3.0 million during the third quarter of 2019, a decrease of 40%. The decrease was primarily attributable to a decrease of $0.2 million in salary and benefits, $0.1 million in facilities and office expense, $0.3 million in insurance expense, $0.6 million in professional fees, and $0.1 million in legal fees offset by an increase of $0.1 million in licenses, taxes and fees.

Total operating expenses for the third quarter of 2020 were approximately $3.9 million, compared to total operating expenses of approximately $5.8 million during the same period of 2019, a decrease of 33%.

As of September 30, 2020, the Companys cash balance was approximately $33.5 million.

Conference Call and Webcast

The conference call is scheduled to begin at 8:00 am ET on Thursday, November 12, 2020. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at http://www.pdsbiotech.com.

After the live webcast, the event will be archived on PDS Biotechs website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13712632.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely, believe, estimate, project, intend, forecast, guidance, outlook and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the Companys dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Companys operations or require the Company to relinquish rights to the Companys technologies or product candidates; the Companys limited operating history in the Companys current line of business, which makes it difficult to evaluate the Companys prospects, the Companys business plan or the likelihood of the Companys successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset PDS0101 and other Versamune based products; the future success of such trials; the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101 and other Versamune based products and the Companys interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the acceptance by the market of the Companys product candidates, if approved; the timing of and the Companys ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Companys product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechnologyPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Jacob GoldbergerCG CapitalPhone: +1 (404) 736-3841Email: jacob@cg.capital

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

September 30, 2020

December 31, 2019

ASSETS

(unaudited)

Current assets:

Cash and cash equivalents

$

33,468,935

$

12,161,739

Prepaid expenses and other

373,395

2,308,462

Total current assets

33,842,330

14,470,201

Property and equipment, net

9,345

21,051

Operating lease right-to-use asset

593,580

Total assets

$

34,445,255

$

14,491,252

LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES

Current liabilities:

Accounts payable

$

1,559,591

$

1,197,720

Accrued expenses

1,222,773

1,097,640

Restructuring reserve

498,185

Operating lease obligation - short term

116,240

Total current liabilities

2,898,604

2,793,545

Noncurrent liability:

Operating lease obligation - long term

521,692

STOCKHOLDERS' EQUITY

Common stock, $0.00033 par value, 75,000,000 shares authorized at September 30, 2020 and December 31, 2019, 22,261,619 shares and 5,281,237 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

7,346

1,742

Additional paid-in capital

70,775,892

40,633,670

Accumulated deficit

(39,758,279

)

(28,937,705

)

Total stockholders' equity

31,024,959

11,697,707

Total liabilities and stockholders' equity

$

34,445,255

$

14,491,252

PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

Read more from the original source:
PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update - Yahoo Finance

Thursday, November 12, 2020, A company in the biotech sector PDS Biotechnology Corporation (Nasdaq: PDSB), publicized its quarterly results for the period ended 30 September 2020 and provided a business update.

Net losses were almost $3.9 million for the third quarter of 2020, or $0.23 per basic share and diluted share, compared to a net loss of approximately $5.8 million for the third quarter of 2019, or $1.10 per basic share and diluted share.

Learn from the #1 Futures Trading Education Institute in the World

Learn a direct approach to trading Futures that provides you with the techniques and the confidence you need to make consistent profits.

***For a limited time, we are offering a FREE CLASS. Dont take our word for how effective our teaching methods are see it for yourself!

Sign up today to receive free access and a guided tour through our program, PATH TO SUCCESS.

Sponsored

For the previous quarter, R&D costs reached about $2.1 million, in contrast to $1.8 million at the same time in 2019, an improvement of 12 percent. The rise was mainly due to an increase in tech addition to operations of $0.1 million and clinical trials of $0.3 million, counterbalanced by a decline in professional fees of $0.1 million and regulatory expenses of $0.1 million.

General and administrative expenses were roughly $1.8 million for the period compared to $3.0 million years over year, which was a decline of 40 percent. The drop was largely due to a $0.2 million cut down in salaries and benefits, $0.1 million in expenditures for services and offices, $0.3 million in insurance costs, $0.6 million in professional fees, and $0.1 million in legal fees, offset by a rise in permits, taxes, and fees of $0.1 million.

Expenses related to the operation were almost $3.9 million for the third quarter, in comparison with total operating expenses of $5.8 million during the same quarter year before, which was a 33 percent decline.

The clinical-stage immunotherapy company that develops novel cancer therapies and medications for transferrable diseases based on the companys patented activating technology Versamune T-cell. Its cash balance was recorded $33.5 million as of September 30, 2020.

PDS Biotechnology Corporation (Nasdaq: PDSB) shares were trading 1.94% away from the 20-day Simple Moving Average. Its last months performance was recorded -9.73% in contrast with the 6 months performance of 151.38%.

More here:
PDS Biotechnology Corporation (PDSB) revealed pretty balanced Earnings results as it emphasizes cost-cutting measures - The News Heater

The Separation Systems for Commercial Biotechnology Market research report is a detailed analysis of the latest developments, market size, status, future technologies, industry drivers, challenges, regulatory guidelines, and the top corporate profiles and player strategies. Research studies give an overview of the Separation Systems for Commercial Biotechnology market is a valuable guidance and guidance tool for companies and individuals interested in predicting the market size by obtaining key statistics based on manufacturers market conditions. Get the report and understand the structure of the details (full index, list of tables and figures, figures).

Download Free Sample Copy of Separation Systems for Commercial Biotechnology market Report:https://www.worldwidemarketreports.com/sample/350683

Detailed qualitative analysis includes identification and investigation of aspects such as market structure, growth drivers, constraints and challenges, new product trends and opportunities. The report also looks at the financial condition of large companies, including gross profit, revenue generation, sales volume, revenue, cost of sales, individual growth rates, and other financial indicators. Basically, the report provides details on all the major market players such as market trends, growth drivers, constraints, opportunities, challenges, future prospects, and , Thermo Fisher Scientific, GE Healthcare, Agilent Technologies;Shimadzu Corporation, bioM rieux SA, Bio-Rad Laboratories, Inc., Hitachi Koki Co., Ltd., Merck & Co., Inc., QIAGEN, WATERS, Sartorius, PerkinElmer, Inc., Danaher, Miltenyi Biotec, BD,.

The Separation Systems for Commercial Biotechnology market is analyzed with a combination of irreplaceable primary knowledge and secondary sources and the best combination of internal methodologies. Real-time market valuation is an important part of market size and forecasting methods. Our panel of industry experts and key participants helped to summarize the relevant aspects using realistic parameter estimates for a comprehensive study.

Factors contributing to the growth of the Separation Systems for Commercial Biotechnology market include an increasing demand for automated solutions, and the need to meet regulatory and efficiency requirements. Additionally, the growing demand for Separation Systems for Commercial Biotechnology and its growing importance in developing countries provide opportunities for market growth.

The report has key sections such as Type and End User along with various segments that determine the outlook for the global Separation Systems for Commercial Biotechnology market. Each type provides data on respect for the business during a speculative period. The application area also provides information on the volume and consumption during the estimated period. Understanding this segment will help readers to recognize the importance of variables that influence market development.

Listed Types are, Microarray, Lab-on-a-chip, Biochip, Magnetic separation, Chromatography, Flow cytometry, Membrane filtration, Electrophoresis, Centrifugation,

Listed Application/ End-Use are, Pharmaceutical, Food & Cosmetics, Agriculture, Others,

Geographically, the market is divided into the major regions of the world, providing a comprehensive analysis of consumption, sales, and market share for the period 2020-2026. Regional divisions include North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Currently, the report analyzes changes in market dynamics and demand patterns related to the COVID-19 epidemic. This report provides a detailed view of business areas, growth prospects, and future prospects based on the impact of COVID-19 on the growth of the entire industry. The report also includes a post-COVID-19 outlook and analysis of the current and future impact of pandemics on the market.

Get the Free Covid-19 Impact Analysis, And All upadates on Separation Systems for Commercial Biotechnology Industry:https://www.worldwidemarketreports.com/covidimpact/350683

Competitive Landscape-

The competitive analysis is one of the best sections of the report, comparing the progress of key players based on key parameters such as market share, new developments, global reach, regional competition, pricing, and production. From the nature of the competition to future changes in the vendor environment, the report provides a detailed analysis of the competition in the global Separation Systems for Commercial Biotechnology market.

Key questions answered in the report:

Thanks for your visit. If you have any other questions, please contact us. Our team will prepare a report tailored to your needs.

https://www.worldwidemarketreports.com/quiry/350683

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

More here:
Global Separation Systems for Commercial Biotechnology Industry Outlook and Growth Forecast for the Period 2020 to 2026 :, Thermo Fisher Scientific,...

Vir Biotechnology Inc. (NASDAQ:VIR) went down by -21.36% from its latest closing price compared to the recent 1-year high of $75.00. The companys stock price has collected -17.01% of loss in the last five trading sessions. Press Release reported on 11/06/20 that Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K

Opinions of the stock are interesting as 5 analysts out of 8 who provided ratings for Vir Biotechnology Inc. declared the stock was a buy, while 0 rated the stock as overweight, 2 rated it as hold, and 0 as sell.

Learn from the #1 Futures Trading Education Institute in the World

Learn a direct approach to trading Futures that provides you with the techniques and the confidence you need to make consistent profits.

***For a limited time, we are offering a FREE CLASS. Dont take our word for how effective our teaching methods are see it for yourself!

Sign up today to receive free access and a guided tour through our program, PATH TO SUCCESS.

Sponsored

The average price from analysts is $54.14, which is $29.49 above the current price. VIR currently public float of 109.06M and currently shorts hold a 6.92% ratio of that float. Today, the average trading volume of VIR was 1.14M shares.

VIR stocks went down by -17.01% for the week, with a monthly drop of -37.61% and a quarterly performance of -51.56%, while its annual performance rate touched 84.45%. The volatility ratio for the week stands at 9.43% while the volatility levels for the past 30 days are set at 7.52% for Vir Biotechnology Inc.. The simple moving average for the period of the last 20 days is -28.59% for VIR stocks with a simple moving average of -30.02% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with BofA Securities repeating the rating for VIR by listing it as a Buy. The predicted price for VIR in the upcoming period, according to BofA Securities is $55 based on the research report published on October 05th of the current year 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR reach a price target of $54, previously predicting the price at $48. The rating they have provided for VIR stocks is Buy according to the report published on September 14th, 2020.

JP Morgan gave a rating of Neutral to VIR, setting the target price at $29 in the report published on September 11th of the current year.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.99% of loss for the given period.

Volatility was left at 7.52%, however, over the last 30 days, the volatility rate increased by 9.43%, as shares sank -41.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.74% lower at present.

During the last 5 trading sessions, VIR fell by -17.01%, which changed the moving average for the period of 200-days by +2.97% in comparison to the 20-day moving average, which settled at $34.83. In addition, Vir Biotechnology Inc. saw 102.86% in overturn over a single year, with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at VIR starting from Parrish Jay, who sale 6,944 shares at the price of $31.27 back on Nov 02. After this action, Parrish Jay now owns 222,222 shares of Vir Biotechnology Inc., valued at $217,153 using the latest closing price.

Virgin Herbert, the EVP, Research & CSO of Vir Biotechnology Inc., sale 3,805 shares at $35.04 during a trade that took place back on Oct 27, which means that Virgin Herbert is holding 23,700 shares at $133,335 based on the most recent closing price.

Current profitability levels for the company are sitting at:

The net margin for Vir Biotechnology Inc. stands at -2158.98. The total capital return value is set at -62.52, while invested capital returns managed to touch -62.97. Equity return is now at value -81.10, with -42.30 for asset returns.

Based on Vir Biotechnology Inc. (VIR), the companys capital structure generated 0.27 points at debt to equity in total, while total debt to capital is 0.27. Total debt to assets is 0.22, with long-term debt to equity ratio resting at 0.21. Finally, the long-term debt to capital ratio is 0.21.

When we switch over and look at the enterrpise to sales, we see a ratio of 119.29, with the companys debt to enterprise value settled at 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.81.

Outsmart Wall Streets Top Options Traders

Its no secret that the market has provided endless opportunities to generate extremely profitable trades this past quarter. Scott Bauer, a professional trader with 25+ years of experience has already been targeting numerous triple-digit wins like these this year aloneHes actually put together a free guide that has 25 winning option strategies.

Click here to access the Options Profits Trading Guide now.

Sponsored

Read more from the original source:
The Chart for Vir Biotechnology Inc. (VIR) Is Flashing Mixed Signals - The News Heater

If you start applying it, and its wrong, and we have no ability to see that its wrong and to fix it, you can cause more harm than good, Jha said. The more confident we get in technology, the more important it is to understand when humans can override these things. I think the Boeing 737 Max example is a classic example. The system said the plane is going up, and the pilots saw it was going down but couldnt override it.

Jha said a similar scenario could play out in the developing world should, for example, a community health worker see something that makes him or her disagree with a recommendation made by a big-name companys AI-driven app. In such a situation, being able to understand how the apps decision was made and how to override it is essential.

If you see a frontline community health worker in India disagree with a tool developed by a big company in Silicon Valley, Silicon Valley is going to win, Jha said. And thats potentially a dangerous thing.

Researchers at SEAS and MGHs Radiology Laboratory of Medical Imaging and Computation are at work on the two problems. The AI-based diagnostic system to detect intracranial hemorrhages unveiled in December 2019 was designed to be trained on hundreds, rather than thousands, of CT scans. The more manageable number makes it easier to ensure the data is of high quality, according to Hyunkwang Lee, a SEAS doctoral student who worked on the project with colleagues including Sehyo Yune, a former postdoctoral research fellow at MGH Radiology and co-first author of a paper on the work, and Synho Do, senior author, HMS assistant professor of radiology, and director of the lab.

We ensured the data set is of high quality, enabling the AI system to achieve a performance similar to that of radiologists, Lee said.

Second, Lee and colleagues figured out a way to provide a window into an AIs decision-making, cracking open the black box. The system was designed to show a set of reference images most similar to the CT scan it analyzed, allowing a human doctor to review and check the reasoning.

Jonathan Zittrain, Harvards George Bemis Professor of Law and director of the Berkman Klein Center for Internet and Society, said that, done wrong, AI in health care could be analogous to the cancer-causing asbestos that was used for decades in buildings across the U.S., with widespread harmful effects not immediately apparent. Zittrain pointed out that image analysis software, while potentially useful in medicine, is also easily fooled. By changing a few pixels of an image of a cat still clearly a cat to human eyes MIT students prompted Google image software to identify it, with 100 percent certainty, as guacamole. Further, a well-known study by researchers at MIT and Stanford showed that three commercial facial-recognition programs had both gender and skin-type biases.

Ezekiel Emanuel, a professor of medical ethics and health policy at the University of Pennsylvanias Perelman School of Medicine and author of a recent Viewpoint article in the Journal of the American Medical Association, argued that those anticipating an AI-driven health care transformation are likely to be disappointed. Though he acknowledged that AI will likely be a useful tool, he said it wont address the biggest problem: human behavior. Though they know better, people fail to exercise and eat right, and continue to smoke and drink too much. Behavior issues also apply to those working within the health care system, where mistakes are routine.

We need fundamental behavior change on the part of these people. Thats why everyone is frustrated: Behavior change is hard, Emanuel said.

Susan Murphy, professor of statistics and of computer science, agrees and is trying to do something about it. Shes focusing her efforts on AI-driven mobile apps with the aim of reinforcing healthy behaviors for people who are recovering from addiction or dealing with weight issues, diabetes, smoking, or high blood pressure, conditions for which the personal challenge persists day by day, hour by hour.

The sensors included in ordinary smartphones, augmented by data from personal fitness devices such as the ubiquitous Fitbit, have the potential to give a well-designed algorithm ample information to take on the role of a health care angel on your shoulder.

The tricky part, Murphy said, is to truly personalize the reminders. A big part of that, she said, is understanding how and when to nudge not during a meeting, for example, or when youre driving a car, or even when youre already exercising, so as to best support adopting healthy behaviors.

How can we provide support for you in a way that doesnt bother you so much that youre not open to help in the future? Murphy said. What our algorithms do is they watch how responsive you are to a suggestion. If theres a reduction in responsivity, they back off and come back later.

The apps can use sensors on your smartphone to figure out whats going on around you. An app may know youre in a meeting from your calendar, or talking more informally from ambient noise its microphone detects. It can tell from the phones GPS how far you are from a gym or an AA meeting or whether you are driving and so should be left alone.

Trickier still, Murphy said, is how to handle moments when the AI knows more about you than you do. Heart rate sensors and a phones microphone might tell an AI that youre stressed out when your goal is to live more calmly. You, however, are focused on an argument youre having, not its physiological effects and your long-term goals. Does the app send a nudge, given that its equally possible that you would take a calming breath or angrily toss your phone across the room?

Working out such details is difficult, albeit key, Murphy said, in order to design algorithms that are truly helpful, that know you well, but are only as intrusive as is welcome, and that, in the end, help you achieve your goals.

For AI to achieve its promise in health care, algorithms and their designers have to understand the potential pitfalls. To avoid them, Kohane said its critical that AIs are tested under real-world circumstances before wide release.

Similarly, Jha said its important that such systems arent just released and forgotten. They should be reevaluated periodically to ensure theyre functioning as expected, which would allow for faulty AIs to be fixed or halted altogether.

Several experts said that drawing from other disciplines in particular ethics and philosophy may also help.

Programs like Embedded EthiCS at SEAS and the Harvard Philosophy Department, which provides ethics training to the Universitys computer science students, seek to provide those who will write tomorrows algorithms with an ethical and philosophical foundation that will help them recognize bias in society and themselves and teach them how to avoid it in their work.

Disciplines dealing with human behavior sociology, psychology, behavioral economics not to mention experts on policy, government regulation, and computer security, may also offer important insights.

The place were likely to fall down is the way in which recommendations are delivered, Bates said. If theyre not delivered in a robust way, providers will ignore them. Its very important to work with human factor specialists and systems engineers about the way that suggestions are made to patients.

Bringing these fields together to better understand how AIs work once theyre in the wild is the mission of what Parkes sees as a new discipline of machine behavior. Computer scientists and health care experts should seek lessons from sociologists, psychologists, and cognitive behaviorists in answering questions about whether an AI-driven system is working as planned, he said.

How useful was it that the AI system proposed that this medical expert should talk to this other medical expert? Parkes said. Was that intervention followed? Was it a productive conversation? Would they have talked anyway? Is there any way to tell?

Next: A Harvard project asks people to envision how technology will change their lives going forward.

Sign up for daily emails to get the latest Harvardnews.

Read the original:
Risks and benefits of an AI revolution in medicine - Harvard Gazette

MALVERN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that the management team will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 at 12:30pm ET. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.About NeuroneticsNeuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.Investor Contact:Mark R. KlausnerWestwicke Partners443-213-0501ir@neuronetics.comMedia Contact:Chelsey MankoVault Communications610-455-2778cmanko@vaultcommunications.com

Link:
Neuronetics to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum

Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases

Read more from the original source:
Retrophin Completes Acquisition of Orphan Technologies

PORTLAND, Maine, Nov. 12, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced unaudited financial results for the quarter ended September 30, 2020.

View original post here:
ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2020

– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb –

See more here:
Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program

MINNEAPOLIS, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter ended September 30, 2020. Management is hosting an earnings call today at 4:30 p.m. ET.

See the rest here:
Sun BioPharma, Inc. Provides Business Update and Reports Q3 2020 Financial Results

EMERYVILLE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today reported financial results for the quarter ended September 30, 2020.

Go here to read the rest:
Berkeley Lights Reports Financial Results for Third Quarter of Fiscal Year 2020

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.

Go here to read the rest:
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update